Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
-
Published:2018-02-28
Issue:3
Volume:8
Page:
-
ISSN:2044-5385
-
Container-title:Blood Cancer Journal
-
language:en
-
Short-container-title:Blood Cancer Journal
Author:
De Stefano Valerio, Carobbio Alessandra, Di Lazzaro Vincenzo, Guglielmelli PaolaORCID, Iurlo Alessandra, Finazzi Maria Chiara, Rumi Elisa, Cervantes Francisco, Elli Elena Maria, Randi Maria Luigia, Griesshammer Martin, Palandri Francesca, Bonifacio Massimiliano, Hernandez-Boluda Juan-Carlos, Cacciola Rossella, Miroslava Palova, Carli Giuseppe, Beggiato Eloise, Ellis Martin H., Musolino Caterina, Gaidano Gianluca, Rapezzi Davide, Tieghi Alessia, Lunghi Francesca, Loscocco Giuseppe Gaetano, Cattaneo Daniele, Cortelezzi Agostino, Betti Silvia, Rossi Elena, Finazzi Guido, Censori Bruno, Cazzola Mario, Bellini Marta, Arellano-Rodrigo Eduardo, Bertozzi Irene, Sadjadian Parvis, Vianelli Nicola, Scaffidi Luigi, Gomez Montse, Cacciola Emma, Vannucchi Alessandro M., Barbui Tiziano
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Reference37 articles.
1. Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391–2405 (2016). 2. Tefferi, A. & Pardanani, A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 1, 97–105 (2015). 3. Patrono, C., Rocca, B. & De Stefano, V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 121, 1701–1711 (2013). 4. Barbui, T., Finazzi, G. & Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood 122, 2176–2184 (2013). 5. Barbui, T. et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 124, 3021–3023 (2014).
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|